Longevity Medicine Clinics and Executive Health Programs
Evidence grade 1 of 5, Untested. Read how the Atlas grades evidence.
Individual diagnostic technologies used (MRI, CT, standard blood biomarkers) are well validated for targeted clinical indications, but their bundled use for routine whole-body screening of asymptomatic people is explicitly not endorsed by major radiology bodies for lack of demonstrated net benefit, and clinic-specific outcome claims are not independently verified.
Reference only. Not medical advice.
Longevity clinics offer paying members, typically for annual membership fees ranging from several thousand to over twenty thousand dollars, a bundle of advanced diagnostics not typically included in routine primary care: whole-body MRI, coronary CT angiography, extensive blood biomarker panels, genetic and sometimes epigenetic testing, and in some cases AI-assisted analysis intended to flag early disease risk before symptoms appear. Fountain Life, one of the best-known brands in this space, offers membership tiers up to roughly 19,500 to 21,500 dollars per year for its most comprehensive package, with clinics operating in multiple US cities and international expansion underway as of the mid-2020s. Competing and adjacent offerings include a growing number of concierge and executive longevity programs run by hospital systems, standalone startups, and physician groups worldwide. The evidentiary and regulatory picture for this category is contested. Professional radiology bodies, including the American College of Radiology, have maintained since at least the mid-2000s and reaffirmed in more recent statements that there is no documented evidence that total-body CT or whole-body MRI screening in asymptomatic, average-risk individuals is cost-effective or extends life, and they do not recommend it outside of specific high-risk groups, such as carriers of Li-Fraumeni syndrome or other hereditary cancer predispositions, where targeted evidence of benefit exists. Systematic reviews of whole-body MRI screening in unselected populations have found substantial rates of incidental findings, in some analyses around 30 percent of scans, many of which prove clinically insignificant after follow-up but generate additional testing, cost, anxiety, and in some cases unnecessary biopsies or procedures, a pattern radiologists and epidemiologists describe as overdiagnosis. Proponents of longevity clinics counter that catching a genuine minority of significant early-stage findings, such as small cancers or coronary disease, can be life-saving for those specific individuals, and that traditional primary care often does not have the time or reimbursement structure to pursue this level of proactive screening. The clinics themselves generally operate within existing medical licensing and imaging regulatory frameworks rather than under any special "longevity medicine" regulatory category, since no such formal specialty or governmental oversight regime currently exists in the United States or most other countries; imaging equipment and CLIA-certified lab testing are regulated, but the packaging, marketing claims, and health-optimization advice built around results are not independently vetted by a medical regulator before sale to consumers. As of the mid-2020s, mainstream medical and public-health bodies broadly agree these programs occupy a genuine and expanding commercial market responding to consumer demand for proactive health information, while cautioning that population-level evidence of net benefit, and independent verification of specific "biological age" or risk-reduction outcomes marketed by individual clinics, remains limited.
Longevity clinics offer paying members, typically for annual membership fees ranging from several thousand to over twenty thousand dollars.
What people get wrong
Nothing recorded here yet. There is almost certainly something people get wrong about this one, and the blank space means we have not written it down, not that the record is clean.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
How we got here
Executive-style comprehensive physical exams have existed for decades, but a distinct "longevity clinic" category combining whole-body imaging, extensive blood biomarker panels, genetic testing, and AI-assisted risk scoring emerged in the late 2010s and accelerated through the early 2020s alongside rising public interest in aging science. Fountain Life, among the most prominent examples, formed in October 2020 when entrepreneurs Peter Diamandis and Tony Robbins merged their diagnostics initiative with physician William Kapp's Longevity Performance Center, later adding physician-scientist Robert Hariri as a co-founder; the category now includes numerous competitors and has expanded from a handful of US clinics to multi-city and international operations.
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Longevity Medicine Clinics and Executive Health Programs. A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
- What can go wrong. We have not written the risk line for this one. Read the safety section below rather than treating its absence as reassurance.
- Where we land. We have not taken a position on this yet.
- What people take it for. We have not catalogued the claims made for it.